Investors Shouldn't Be Too Comfortable With SELVAS Healthcare's (KOSDAQ:208370) Earnings

Despite posting some strong earnings, the market for SELVAS Healthcare, Inc.'s (KOSDAQ:208370) stock hasn't moved much. Our analysis suggests that shareholders have noticed something concerning in the numbers.

View our latest analysis for SELVAS Healthcare

In order to understand the potential for per share returns, it is essential to consider how much a company is diluting shareholders. As it happens, SELVAS Healthcare issued 18% more new shares over the last year. That means its earnings are split among a greater number of shares. Per share metrics like EPS help us understand how much actual shareholders are benefitting from the company's profits, while the net income level gives us a better view of the company's absolute size. Check out SELVAS Healthcare's historical EPS growth by clicking on this link.

A Look At The Impact Of SELVAS Healthcare's Dilution On Its Earnings Per Share (EPS)

SELVAS Healthcare has improved its profit over the last three years, with an annualized gain of 581% in that time. In comparison, earnings per share only gained 514% over the same period. And at a glance the 84% gain in profit over the last year impresses. On the other hand, earnings per share are only up 71% in that time. So you can see that the dilution has had a bit of an impact on shareholders.

In the long term, earnings per share growth should beget share price growth. So it will certainly be a positive for shareholders if SELVAS Healthcare can grow EPS persistently. However, if its profit increases while its earnings per share stay flat (or even fall) then shareholders might not see much benefit. For the ordinary retail shareholder, EPS is a great measure to check your hypothetical "share" of the company's profit.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of SELVAS Healthcare.

Our Take On SELVAS Healthcare's Profit Performance

SELVAS Healthcare shareholders should keep in mind how many new shares it is issuing, because, dilution clearly has the power to severely impact shareholder returns. Therefore, it seems possible to us that SELVAS Healthcare's true underlying earnings power is actually less than its statutory profit. But on the bright side, its earnings per share have grown at an extremely impressive rate over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. In terms of investment risks, we've identified 1 warning sign with SELVAS Healthcare, and understanding it should be part of your investment process.

Today we've zoomed in on a single data point to better understand the nature of SELVAS Healthcare's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.